Senolytic Supplement Shifts Key Aging Chemokines in Healthy Adults

Cellular senescence—the stable arrest of damaged cells that refuse to die—accumulates with age and drives systemic inflammation through the senescence-associated secretory phenotype (SASP). Reducing senescent cell burden or dampening the SASP is a leading strategy for extending healthspan. This pilot study asked whether a brief, two-day course of a botanically complex nutraceutical could produce detectable shifts in circulating SASP proteins in healthy older adults, following the 'hit-and-run' intermittent dosing rationale pioneered at the Mayo Clinic.

The study enrolled 71 adults aged 45–79 in a fully decentralized, single-arm design (NCT06953518). Participants took Qualia Senolytic—a 12-capsule, two-day regimen containing fisetin, quercetin phytosome, Longvida curcumin, olive leaf extract, soy isoflavones, luteolin, milk thistle silymarin, piperlongumine, and Senactiv (Panax notoginseng + Rosa roxburghii). Fingerstick blood samples were collected at baseline (day 0) and follow-up (day 7). Plasma proteins were quantified using the Olink Target 48 Cytokine proximity extension assay. Quality of life was assessed via RAND-36, DASS, AMFS, and FIFE questionnaires. Fifty-three participants (74.6%) provided analyzable paired samples. Data were analyzed with linear mixed models and Wilcoxon signed-rank tests.

None of the four pre-specified primary SASP outcomes—TNF, IL-1β, CXCL8 (IL-8), and VEGFA—changed significantly after correction for multiple comparisons. In unadjusted exploratory analyses, however, four chemokines decreased significantly: CXCL9 (MIG), CXCL10 (IP-10), CCL8 (MCP-2), and CXCL11 (I-TAC). CXCL9 and CXCL10 are particularly well-established SASP components, frequently elevated in aged tissues and senescent cell conditioned media. Conversely, IL-17F and oncostatin M (OSM) increased significantly—findings the authors flag as potentially representing compensatory immune signaling or off-target effects warranting further scrutiny. Quality of life metrics improved across multiple domains, though the absence of a placebo arm makes interpretation of subjective outcomes unreliable due to expectation effects.

Feasibility benchmarks were largely met: 97.2% of enrolled participants received the intervention, no discontinuations occurred due to adverse effects, and participant satisfaction averaged 4.7 out of 5. Specimen logistics—14 samples excluded due to insufficient volume, delays, or packaging failures—was identified as the primary operational challenge for future scale-up. The fingerstick plus Olink pipeline was validated as sensitive enough to detect protein-level changes after short-term supplementation, which is a meaningful technical confirmation.

The authors are transparent about the study's exploratory nature. The lack of a control arm, small sample size, short follow-up, industry funding, and the absence of direct senescent cell burden measurements (e.g., p16INK4a tissue staining or p21 levels) all limit causal inference. The reductions in CXCL9, CXCL10, and related interferon-gamma-inducible chemokines are biologically plausible given the anti-inflammatory properties of fisetin, quercetin, luteolin, and curcumin, but the effect sizes and clinical significance remain unestablished. The authors recommend a randomized, placebo-controlled trial powered on CXCL9 and CXCL10 as primary endpoints.